NCT00192621View on ClinicalTrials.gov

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
HIV InfectionsDyslipidemiasGlucose Metabolism DisordersMetabolic DiseasesLipodystrophyCardiovascular Disease
Interventions
DRUG

Combivir (zidovudine [AZT] / lamivudine [3TC])

DRUG

Kaletra (lopinavir [LPVr])

Trial Locations (1)

2010

St Vincents Hospital, Sydney

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
collaborator

St Vincent's Hospital, Sydney

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Garvan Institute of Medical Research

OTHER

collaborator

Prince of Wales Hospital, Sydney

OTHER_GOV

lead

Kirby Institute

OTHER_GOV